Open AccessEculizumab exposure in children and young adults: indications, practice patterns, and outcomes—a Pediatric Nephrology Research Consortium study
Author(s) -
Melissa MuffLuett,
Keia Sanderson,
Rachel M. Engen,
Rima S. Zahr,
Scott E. Wenderfer,
Cheryl L. Tran,
Sheena Sharma,
Yi Cai,
Susan E. Ingraham,
Erica Winnicki,
Donald J. Weaver,
Tracy E. Hunley,
Stefan G. Kiessling,
Meredith Seamon,
Robert P. Woroniecki,
Yosuke Miyashita,
Nianzhou Xiao,
Abiodun Aderogba Omoloja,
Sarah J. Kizilbash,
Asif Mansuri,
Mahmoud Kallash,
Yi-chun Yu,
Ashley Sherman,
Tarak Srivastava,
Carla M. Nester
Publication year - 2021
Publication title -
pediatric nephrology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.831
H-Index - 107
eISSN - 1432-198X
pISSN - 0931-041X
DOI - 10.1007/s00467-021-04965-5
Subject(s) - eculizumab , medicine , nephrology , retrospective cohort study , cohort , dosing , adverse effect , atypical hemolytic uremic syndrome , pediatrics , cohort study , intensive care medicine , immunology , antibody , complement system
Eculizumab is approved for the treatment of atypical hemolytic uremic syndrome (aHUS). Its use off-label is frequently reported. The aim of this study was to describe the broader use and outcomes of a cohort of pediatric patients exposed to eculizumab.